| Wednesday, October 29 |
| 11:00 am - 7:00 pm |
Registration Open |
| |
|
| Thursday, October 30 |
| 6:30 am - 6:00 pm |
Registration Open |
| |
|
| Friday, October 31 |
| 6:30 am - 5:00 pm |
Registration Open |
| 10:00 am - 4:00 pm |
Exhibit Hall Open |
| 10:00 am - 7:30 pm |
Poster Hall Open |
| 7:50 am - 8:00 am |
President's Welcome
Jon M. Wigginton, MD - Merck & Co., Inc.
|
| 8:00 am - 8:45 am |
Richard V. Smalley, MD Memorial Lectureship
Different Tumor Antigens in the Immunotherapy of Cancer: Are we Selecting the Right
Target?
 Giorgio Parmiani, MD - San Raffaele Foundation
|
| 8:45 am - 11:30 am |
Plenary Session: Enhancing Cancer Vaccines
| Co-Chairs: |
Glenn Dranoff, MD - Dana-Farber Cancer Institute
W. Martin Kast, PhD - University of Southern California
|
|
| 8:45 am - 9:15 am
| Enhancing Cancer Vaccines Through Heterologous Prime Boost Strategies that Include VRP and that Induce Lifelong Protection from Prostate Cancer and Therapy of Cervical Cancer in Mice and Robust Cell-Mediated Immunity in Rhesus Macaques
W. Martin Kast, PhD - University of Southern California |
| 9:15 am - 9:30 am |
Interleukin-15 and its Receptor Enhance Antitumor Activity Following a Genetically-Modified Dendritic Cell Vaccine
Jason C. Steel, PhD - National Cancer Institute, Metabolism Branch, NIH |
| 9:30 am - 9:45 am |
T Cell Receptor-Dependent and Independent Pathways Control PD-1 Expression on CD8+ T cells Generated upon Intra Lymph Node Immunization
Adrian Bot, MD, PhD - MannKind Corporation |
| 9:45 am - 10:00 am |
Cellular Immunotherapy and Immune Regulation in Ovarian Cancer
Martin J. Cannon, PhD - University of Arkansas for Medical Sciences |
| 10:00 am - 10:15 am |
Intra-Lymphatic Continuous Infusion of Dendritic Cells in Patients with Advanced Melanoma: Early Indication of Clinical Efficacy
Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute |
| 10:45 am - 11:00 am |
Clinical Response to the MAGE-A3 Immunotherapeutic in Metastatic Melanoma Patients is Associated with a Specific Gene Expression Profile Present at the Tumor Site
Jamila Louahed, PhD - GlaxoSmithKline Biologicals SA |
| 11:00 am - 11:30 am |
Balancing Tumor Immunity and Inflammation
Glenn Dranoff, MD - Dana-Farber Cancer Institute |
| 11:30 am - 1:00 pm |
Lunch with Poster Viewing |
| 1:00 pm - 3:00 pm |
Plenary Session: Adoptive Transfer
| Co-Chairs: |
Helen E. Heslop, MD - Baylor College of Medicine
William J. Murphy, PhD - University of Nevada, School of Medicine
|
|
| 1:00 pm - 1:30 pm |
Three Ways to Enhance the Destructive Power of Tumor-Specific T Cells
Nicholas P. Restifo, MD - National Cancer Institute |
| 1:30 pm - 2:00 pm |
Engineering GVL by T-Cell Genetic Modification
Michael C.V. Jensen, MD - City of Hope / Beckman Research Institute |
| 2:00 pm - 2:15 pm |
Targeted Elimination of Brain Tumor Stem Cells with T Cell Therapies
Christine Brown, PhD - City of Hope National Medical Center |
| 2:15 pm - 2:30 pm |
Intralesional Placement of Lymphokine-Activated Killer Cells After Resection of Primary Glioblastoma
Robert O. Dillman, MD, FACP - Hoag Cancer Center |
| 2:30 pm - 2:45 pm |
Provision of CD4+ T Cell Help Prevents Tolerization of Tumor-Specific CTLs and
Enhances Tumor Immunity in a Murine Model of Prostate Cancer
Kimberly A. Shafer-Weaver, PhD - SAIC/NCI-Frederick |
| 2:45 pm - 3:00 pm |
Rapid Expansion of Melanoma TIL in Adoptive Cell Therapy Leads to Loss of CD28 and
Reduced Proliferative Potential in the MART-1-Specific T Cell Population
Yufeng Li - MD Anderson Cancer Center |
| 3:15 pm - 4:45 pm |
Concurrent Session I: TH-17, Cytokines and T Cell Subsets
| Co-Chairs: |
Martin Oft, MD - Schering-Plough Biopharma (formerly DNAX)
Hideaki Tahara, MD, PhD - University of Tokyo
|
|
| 3:15 pm - 3:40 pm |
IL-23 Promotes Tumor Associated Inflammation and Subverts Immune Surveillance
Martin Oft, MD - Schering-Plough Biopharma (formerly DNAX) |
| 3:40 pm - 4:05 pm |
Potent Anti-Tumor Immunity and Both TH-1 and TH-17 Promotion Associated with
IL-23 Administration
Hideaki Tahara, MD, PhD - University of Tokyo |
| 4:05 pm - 4:30 pm |
TH-17 Cells in Ovarian Cancer Patients
Ilona Kryczek, PhD - University of Michigan |
| 4:30 pm - 4:45 pm |
CD40 Dependent Induction of TH-17 Effector Cells from T Regulatory Cells Using the
Immune Modulator B7-DC XAb
Suresh Radhakrishnan, PhD - Mayo Clinic, College of Medicine
This abstract was fully retracted May 28, 2010 upon request of the Principal Investigator. |
| 3:15 pm - 4:45 pm |
Concurrent Session II: Endpoints, Response Criteria for Clinical Trial Design
| Co-Chairs: |
Thomas A. Davis, MD - AVANT Immunotherapeutics, Inc.
Jeffrey Schlom, PhD - National Cancer Institute, NIH
|
|
| 3:15 pm - 3:40 pm |
Immunotherapies in Combination with Other Therapeutic Modalties: New Paradigms for Clinical Trial Design
Jeffrey Schlom, PhD - National Cancer Institute, NIH |
| 3:40 pm - 3:55 pm |
Overall Survival and New Patterns of Response in Patients with Advanced Melanoma Treated with Ipilimumab
Steven J. O'Day, MD - The Angeles Clinic and Research Institute |
| 3:55 pm - 4:15 pm |
Endpoints for Biologic Therapeutics in Oncology
Peter Bross, MD - FDA - Office of Cellular, Tissue, and Gene Therapies |
| 4:15 pm - 4:45 pm |
Panel Discussion |
| 5:00 pm - 5:30 pm |
iSBTc Membership Business Meeting (iSBTc Members Only) |
| 5:30 pm - 7:30 pm |
Reception with Poster Viewing |
| |
|
| Saturday, November 1 |
| 7:00 am - 6:00 pm |
Registration Open |
| 7:00 am - 8:00 am |
Continental Breakfast |
| 8:00 am - 8:45 am |
Keynote Address
Cancer Immunoediting: Distinct Roles for Innate and Adaptive Immunity in Cancer Control and Promotion
Robert D. Schreiber, PhD - Washington University in St. Louis
|
| 8:45 am - 11:30 am |
Plenary Session: Tumor Escape / Tumor Microenvironment
| Co-Chairs: |
Thomas F. Gajewski, MD, PhD - University of Chicago
Weiping Zou, MD, PhD - University of Michigan
|
|
| 8:45 am - 9:15 am |
Innate Immune Signals that Mediate Host Awareness of Tumor and Promote Adaptive
Immune Responses Against Tumor Antigens
Thomas F. Gajewski, MD, PhD - University of Chicago |
| 9:15 am - 9:30 am |
Persistent High Grade Cervical Dysplasia Excludes CD8+ T Cells
Cornelia Trimble, MD - Johns Hopkins University |
| 9:30 am - 10:00 am |
Inhibitory B7 Family Members (B7-H1 and B7-H4) in the Tumor Microenvironment
Weiping Zou, MD, PhD - University of Michigan |
| 10:00 am - 10:15 am |
L-Arginine Availability Regulates Cyclin D3 mRNA Stability in Human T Cells by Controlling HuR Expression
Paulo C. Rodriguez, PhD - Louisiana State University Health Science Center |
| 10:45 am - 11:15 am |
Correcting the Anergy of Human Tumor-Infiltrating Lymphocytes?
Pierre van der Bruggen, PhD - Ludwig Institute for Cancer Research |
| 11:15 am - 11:30 am |
Evidence for Selection of a Resistant Tumor Microenvironment Following Successful Clinical Response to a Multi-Peptide + IL-12 Melanoma Vaccine
Yuanyuan Zha, PhD - Human Immunologic Monitoring Facility, University of Chicago |
| 11:30 am - 1:00 pm |
Lunch with Poster Viewing |
| 1:00 pm - 2:20 pm |
iSBTc Presidential Abstract Session
| Chair: |
Jon M. Wigginton, MD - Merck & Co., Inc.
|
|
| 1:00 pm - 1:20 pm |
Increasing Immunostimulatory Ability of Tolerogenic APCs Enhances Anti-Tumor Immunity
Stephanie K. Watkins, PhD - National Cancer Institute - Frederick, NIH |
| 1:20 pm - 1:40 pm |
CCL28 a New Link Between Hypoxia Angiogenesis and Tumor Immune Evasion
Andrea Facciabene, PhD - University of Pennsylvania |
| 1:40 pm - 2:00 pm |
Cytotoxic T Lymphocyte-associated Antigen 4 Blockade Enhances Polyfunctional NY-ESO-1 Specific T Cell Responses in Metastatic Melanoma Patients with Tumor Regression
Jianda Yuan, MD, PhD - Memorial Sloan-Kettering Cancer Center |
| 2:00 pm - 2:20 pm |
Radiofrequency Ablation with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect Against Murine Colon Adenocarcinoma
Erik Johnson, MD - University of Wisconsin-Madison |
| 2:45 pm - 4:15 pm |
Concurrent Session I: Tumor Targeting Monoclonal Antibodies
| Co-Chairs: |
Helen Chen, MD - National Cancer Institute, CTEP
Greg Lazar, PhD - Xencor, Inc.
|
|
| 2:45 pm - 3:15 pm |
Antibody and Small Moldular Immune Pharmaceutical Therapies for Patients with Chronic Lymphocytic Leukemia: A Major Step Forward
John C. Byrd, MD - The Ohio State University |
| 3:15 pm - 3:30 pm |
Phase I/II Study of CR011-vcMMAE, an Antibody-Drug Conjugate Targeting GPNMB, for the Treatment of Patients with Advanced Melanoma
Patrick Hwu, MD - MD Anderson Cancer Center |
| 3:30 pm - 4:00 pm |
Optimizing Engagement of the Immune System by Anti-Tumor Antibodies
John R. Desjarlais, PhD - Xencor, Inc. |
| 4:00 pm - 4:15 pm |
Cetuximab Mediated Antibody Dependent Cellular Cytotoxicity by NK Cells Expressing Polymorphic Fc Gamma Receptor (FcyR)IIIa
Robert L. Ferris, MD, PhD - University of Pittsburgh Cancer Institute |
| 2:45 pm - 4:15 pm |
Concurrent Session II: Innate Immunity to Tumors
| Co-Chairs |
David Raulet, PhD - University of California, Berkeley
Giorgio Trinchieri, MD - National Cancer Institute
|
|
| 2:45 pm - 3:15 pm |
Innate Resistance, Inflammation, and Cancer
Giorgio Trinchieri, MD - National Cancer Institute |
| 3:15 pm - 3:45 pm |
Role of NKG2D in Tumor Surveillance
David Raulet, PhD - University of California, Berkeley |
| 3:45 pm - 4:00 pm |
Innate Immunity Can Contribute to the Shaping of Tumor Immunogenicity in the Absence of Adaptive Immunity
Jack D. Bui, MD, PhD - University of California, San Diego |
| 4:00 pm - 4:15 pm |
Spontaneous CTL-mediated Rejection of GP33-positive Lewis Lung Carcinoma is Dependent on an IFNAR Competent Environment
Ulrich Kalinke, PhD - TWINCORE, Centre for Experimental and Clinical Infection Research |
| 4:30 pm - 5:00 pm |
Update: 2007 Workshop on Future Opportunities for Combination Biological
Therapy of Cancer
| Speaker: |
Jon M. Wigginton, MD - Merck & Co., Inc.
|
|
| 5:00 pm - 5:15 pm |
Award Presentations |
| 5:15 pm - 7:00 pm |
Presidential Reception with Poster Viewing |
| |
|
| Sunday, November 2 |
| 7:00 am - 11:00 am |
Registration Open |
| 8:00 am - 10:15 am |
Plenary Session: Cancer Stem Cells and the Host Response
| Co-Chairs: |
Madhav Dhodapkar, MD - The Rockefeller University
Max Wicha, MD - University of Michigan
|
|
| 8:00 am - 8:42 am |
Regulation of Breast Cancer Stem Cells by the Microenvironment
Max Wicha, MD - University of Michigan |
| 8:42 am - 9:24 am |
Harnessing the Immune System to Target Stem Cell Genes in Myeloma
Madhav Dhodapkar, MD - The Rockefeller University |
| 9:24 am - 9:49 am |
Characterization of the Immune Profile of Cancer Stem Cells Isolated from Human Glioblastoma
Cristina Maccalli, PhD - San Raffaele Foundation Scientific Institute |
| 9:49 am - 10:15 am |
CD133 as a Potential Target of Anti-cancer Stem Cell Immunotherapy: Identification of a HLA-A*02 Restricted CD133 Epitope
John S. Yu, MD - Cedars Sinai Medical Center |
| 10:15 am - 10:30 am |
Annual Meeting Adjourns |
| |
| Sunday Hot Topic Symposium |
| 10:30 am - 12:00 pm |
Hot Topic Session - "Anti-CTLA-4: Issues in Development and Regulatory Approval"
Program to include invited speakers, panel discussion/debate and audience questions.
Click here for more information, including a detailed schedule and faculty listing.
|
